GlassScriptPhysician profile
Ngozi Sheila Eboru
NPI 1033861067
$23,726.42
in general payments reported to CMS, 2019-2025
17 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $256 · 2023: $1,003 · 2024: $2,262 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $6,103 · Travel and Lodging: $750 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,500.00 |
| Food and Beverage | $6,102.67 |
| Travel and Lodging | $750.40 |
| Education | $117.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19,337.04 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $829.83 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $677.74 | 2023-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $553.24 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $475.17 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $457.37 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $379.25 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $332.66 | 2024-2025 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $144.08 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $128.50 | 2024-2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $124.99 | 2025 | Jornay Pm |
| Indivior INC. | $98.52 | 2023-2024 | Perseris, Sublocade |
| Janssen Scientific Affairs, LLC | $72.71 | 2024 | Invega Sustenna |
| Dexcom, INC. | $49.72 | 2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $24.16 | 2024 | Gardasil, Rotateq, Vaxelis |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $20.86 | 2024 | Rexulti |
| Noven Therapeutics, LLC | $20.58 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ngozi Eboru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.